Prognostic significance of p53 expression in ovarian granulosa cell tumors

Gynecologic Oncology

Volumn 66, Issue 3, 1997, Pages 475-479

  Ala Fossi, Sirkka Liisa ^a   Mäenpää, Juhani ^a   Aine, Risto ^a   Koivisto, Pasi ^b   Koivisto, Anna Maija ^c   Punnonen, Reijo ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT TRANSFORMATION; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 0031240020     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4803     Document Type: Article

References (25)

1. 1. Chadha S, Cornelisse CJ, Schaberg A: Flow cytometric DNA ploidy analysis of ovarian granulosa cell tumors. Gynecol Oncol 36:240-245, 1990
2. 2. Klemi PJ, Joensuu H, Salmi T: Prognostic value of flow cytometric DNA content analysis in granulosa cell tumor of ovary. Cancer 65:1189-1193, 1990
3. 3. Haba R, Miki H, Kobayashi S, Ohmori M: Combined analysis of flow cytometry and morphometry of ovarian granulosa cell tumor. Cancer 72:3258-3262, 1993
4. 4. Roush GR, El-Naggar AK, Abdul-Karim FW: Granulosa cell tumor of ovary: a clinicopathologic and flow cytometric DNA analysis. Gynecol Oncol 56:430-434, 1995
5. 5. King LA, Okagaki T, Gallup DG, Twiggs LB, Messing MJ, Carson LF: Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis. Gynecol Oncol 61:227-232, 1996
6. 6. Palmquist Evans M, Webb MJ, Gaffey TA, Katzmann JA, Suman VJ, Hu TC: DNA ploidy of ovarian granulosa cell tumors. Lack of correlation between DNA index or proliferative index and outcome in 40 patients. Cancer 75:2295-2298, 1995
7. 7. Klemi PJ, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H: p53 detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76:1201-1208, 1995
8. 8. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al: Overexpression and mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Cancer Res 51:2979-2984, 1991
9. 9. Kappes S, Milde-Langosch K, Kressin P, Passlack B, Dockhorn-Dworniczak B, Röhlke P, Löning T: p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 64:52-59, 1995
10. 10. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ: Activating mutations for transforming by p53 produce a gene product that forms hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539, 1988
11. 11. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
12. 12. Midgley CA, Fischer CJ, Bartek J, Vojtesek B, Lane D, Barnes DM: Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 101:183-189, 1992
13. 13. Vojtesek B, Bartek J, Midgley CA, Lane DP: An immunohistochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244, 1992
14. 14. Peacock CS, Thompson IW, Van Noorden S: Silver enhancement of polymerised diaminobenzidine: increased sensitivity for immunoperoxidase staining. J Clin Pathol 44:756-758, 1991
15. 15. Headley DW, Frielander ML, Taylor IW, Ruff CA, Musgrove EA: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333-1335, 1983
16. 16. Kallioniemi O-P: Comparison of fresh and paraffin-embedded tissues as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry 9:164-169, 1988
17. 17. Kallioniemi O-P, Visakorpi T, Holli K, Heikkinen A, Isola J, Koivula T: Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting nuclear slicing. Cytometry 12:413-421, 1991
18. 18. Fox H, Agrawal K, Langley F: A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 35:231-241, 1975
19. 19. Evans AT III, Gaffey TA, Malkasian GD, Annegers JF: Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 55:231-238, 1980
20. 20. Novak ER, Kutchmeshgi J, Mupas RS, Woodruff JD. Feminizing gonadal stromal tumors: analysis of the granulosa-theca cell tumors of the ovarian tumor registry. Obstet Gynecol 38:701-713, 1971
21. 21. Stenwig JT, Hazekamp JT, Beecham JB. Granulosa cell tumors of the ovary: a clinicopathological study of 118 cases with long-term follow-up. Gynecol Oncol 7:136-152, 1979
22. 22. Malmström H, Högberg T, Risberg B, Simonsen E: Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 52:50-55, 1994
23. 23. Ohel G, Kaneti H, Schenker JG. Granulosa cell tumors in Israel: a study of 172 cases. Gynecol Oncol 55:278-286, 1985
24. 24. Liu F-S, Shih-Chu E, Lai C-R, Chen J-T, Shih RT-P, Yang C-H, Tsao C-M: Overexpression of p53 is not a feature of ovarian granulosa cell tumors. Gynecol Oncol 61:50-53, 1996
25. 25. Costa MJ, Walls J, Ames P, Roth LM: Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior. Hum Pathol 27:274-281, 1996